G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC
Trilaciclib Reduces Hospitalizations and Myelosuppressive Events in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) and May Improve Survival
G1 Therapeutic's COSELA (trilaciclib) included in ASCO's updated SCLC treatment guidelines
- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events (HAEs) Including Neutropenia, Anemia, and Thrombocytopenia - - Analyses Showed...
Feb 13 (Reuters) - G1 Therapeutics Inc (GTHX.O) said on Monday it would terminate a late-stage study of its lead drug as it was unlikely to be effective in extending survival in patients with a type of colorectal cancer, sending its shares plunging more than 50%.
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
RESEARCH TRIANGLE PARK, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today described safety data from the first 18 patients enrolled in its ongoing Phase 2, single arm study of trilaciclib administered prior to the antibody-drug conjugate (ADC), sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). These initial data highlight the potential for trilaciclib to meaningfully reduce adverse events related to use of sacituzumab.
RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized in PRESERVE 2, G1’s Phase 3 clinical trial of trilaciclib in patients with metastatic triple negative breast cancer (TNBC) receiving chemotherapy. The trial includes 187 patients receiving first line trilaciclib or placebo prior to gemcitabine and carboplatin (GC).
RESEARCH TRIANGLE PARK, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the last patient has been randomized...